AI News

Unbounded Evolution Completes Over 100 Million Yuan Pre-A Round Financing, Sequoia China Continues to Increase Investment in AI Virtual Cell Models

WallstreetcnUpdated Nov 16 21:06

AI summary

Beijing Unbounded Evolution Technology Co., Ltd. announced on November 16 that it has completed over 100 million yuan in Pre-A round financing, jointly invested by Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund and Detong Capital, among others, with existing shareholders Shunwei Capital, Sequoia China and Songhe Capital continuing to add investment. The funds will be used for basic large model research and development, expansion of the high-throughput automated dry-wet closed-loop system, and industrial ecosystem development. Its self-developed OCOO-T model achieved leading performance in evaluations on three public single-cell perturbation datasets, Tahoe100M, Replogle and PBMC, and the scientific research workbench Karl Workbench ranked first in comprehensive scores in the two scenarios of single-cell omics and spatial omics in the SciAgentArena retest.

Body · AI translation

On November 16, Beijing Wujie Evolution Technology Co., Ltd. (hereinafter referred to as "Wujie Evolution") announced the completion of over 100 million yuan in Pre-A round financing, jointly invested by institutions including Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund and Detong Capital, with existing shareholders Shunwei Capital, Sequoia China and Songhe Capital continuing to increase their investment. The funds from this round will be used for basic large model research and development, expansion of the high-throughput automated dry-wet closed-loop system, and industrial ecosystem development.

This is Wujie Evolution's second financing round this year. In June, the company completed tens of millions of yuan in angel round financing, with investors including Shunwei Capital, Sequoia China and Songhe Capital.

Wujie Evolution was incubated internally by the Hong Kong-listed company XtalPi (2228.HK), and Lai Lipeng, co-founder and Chief Innovation Officer of XtalPi, serves as co-founder of Wujie Evolution.

Wujie Evolution mainly develops AI virtual cell models, using large-scale biological data to predict changes in cells under external interventions such as drugs and gene editing. The company's self-developed foundational model OCOO covers multi-omics research of cells, among which OCOO-T is specifically targeted at transcriptomic data to predict changes in gene expression after cells are subjected to intervention.

Wujie Evolution disclosed that OCOO-T achieved leading performance in evaluations on three public single-cell perturbation datasets: Tahoe100M, Replogle and PBMC. The company also launched the research workbench Karl Workbench, claiming that in the retest of the public scientific research Agent benchmark SciAgentArena, it ranked first in comprehensive scores in the two scenarios of single-cell omics and spatial omics. The above results mainly come from disclosures by the company and the research team, and cannot yet directly correspond to predictive effects in actual drug research and development.

In February 2023, AI protein design company MoleculeMind completed over 100 million yuan in financing, led by Cathay Biotech, with Sequoia China, the previous lead investor in the angel round, continuing to increase its investment.

In September this year, Reuters reported that Anew Labs, an AI drug research and development enterprise spun off from ByteDance, completed $290 million in financing at a post-investment valuation of approximately $1.5 billion, led by HSG (formerly Sequoia China), IDG Capital and GL Ventures under Hillhouse, with Five Source Capital co-leading. Anew Labs is mainly engaged in biomolecular structure prediction, antibody design and drug research and development.

Virtual cells are an emerging research direction in AI life sciences in recent years. In December 2024, researchers affiliated with Stanford University, Genentech and the Chan Zuckerberg Initiative (CZI) published an article in Cell, proposing a research framework for using AI and large-scale biological data to build virtual cells and simulate the behavior of cells and their internal biomolecules.

Beyond capital, model licensing transactions have also begun to appear in this field. In January this year, GSK signed a five-year cooperation agreement with the U.S. virtual cell company Noetik, obtaining a non-exclusive license to Noetik's OCTO-VC model for research on non-small cell lung cancer and colorectal cancer. The agreement includes a total of $50 million in upfront and near-term milestone payments, plus an annual model licensing fee.

At present, the bottlenecks faced by virtual cell models include data supply and experimental validation. A white paper released by Arterial Think Tank in September pointed out that high-quality cell perturbation data is costly to obtain, some pharmaceutical companies' internal experimental data is difficult to share, and there is still a lack of generally applicable validation and feedback mechanisms between model predictions and actual experimental results.

Wujie Evolution is building an automated experimental platform covering processes such as cell culture, perturbation and multi-omics detection. According to the company's plan, the model will be used to propose experimental directions, and experimental results will then be used to validate predictions and improve the model.

The list of 2026 Beijing Key Laboratories announced by Peking University Health Science Center in June this year shows that Wujie Evolution is one of the co-building units of the Beijing Key Laboratory of Hepatobiliary and Pancreatic Tumor Organoid Culture and Intelligent Diagnosis and Treatment, which is built with Peking University First Hospital as the relying institution.

For Wujie Evolution, the public progress at the current stage is mainly concentrated in model evaluation, experimental platform construction and scientific research cooperation. The company has not yet disclosed model licensing revenue, the scale of paying customers, or validation results of actual drug research and development projects.

With the investment of this round of funds, the model's predictive performance in real experiments, the efficiency of data feedback, and whether scientific research cooperation can be converted into commercial orders will become developments that need to be observed going forward. Risk Disclosure and Disclaimer

Markets carry risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the special investment objectives, financial conditions or needs of individual users. Users should consider whether any opinions, views or conclusions in this article are suitable for their particular circumstances. Investment based on this article is at one's own risk.

Source

Wallstreetcn